TY  - GEN
AU  - Morschhauser,Franck
AU  - Mounier,Nicolas
AU  - Sebban,Catherine
AU  - Brice,Pauline
AU  - Solal-Celigny,Phillippe
AU  - Tilly,Herve
AU  - Feugier,Pierre
AU  - Fermé,Christophe
AU  - Copin,Marie Christine
AU  - Lamy,Thierry
TI  - Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS)
SN  - 0008-543X
PY  - 2010///1020
KW  - Adult
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Drug Administration Schedule
KW  - Drug Resistance, Neoplasm
KW  - Female
KW  - Humans
KW  - Lymphoma, Follicular
KW  - drug therapy
KW  - Male
KW  - Middle Aged
KW  - Mitoxantrone
KW  - Neoplasms, Second Primary
KW  - epidemiology
KW  - Recurrence
KW  - Rituximab
KW  - Tumor Burden
KW  - Vidarabine
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1002/cncr.25280
ER  -